

RADIOACTIVE IODINE IN THYROID CANCER: PAST, PRESENT AND FUTURE DIRECTIONS



Tania Jaber, MD

Wednesday Oct 11, 2017

3:30 PM – 4:30 PM

Lecture Hall 2

Target Audience:

Professionals across the healthcare spectrum including physicians, pharmacists, nurses, medical educators, students and other healthcare providers.

Course Objectives:

At the end of the session, participants will be able to:

1. Define the role of radioactive iodine in the treatment of thyroid cancer
2. Recognise when radioactive iodine therapy should be used in thyroid cancer
3. Describe novel uses for radioactive iodine in thyroid cancer

CME Accreditation and Credit Designation Statements

Weill Cornell Medicine-Qatar is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Weill Cornell Medicine-Qatar designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is an Accredited Group Learning Activity (Category 1) as defined by the Qatar Council for Healthcare Practitioners-Accreditation Department and is approved for a maximum of 1 hour.

Faculty Disclosure: It is the policy of Weill Cornell Medicine-Qatar to adhere to Qatar Council for Healthcare Practitioners (QCHP) and Accreditation Council for Continuing Medical Education (ACCME) Criteria, Policies, and Standards for Commercial Support and content validation in order to ensure fair balance, independence, objectivity, and scientific rigor in all its sponsored programs. All faculty participating in sponsored programs are expected to disclose relevant financial relationships pertaining to their contribution to the activity, and any discussions of off-label or investigational uses of approved commercial products or devices, or of any products or devices not yet approved in the United States and elsewhere. WCM-Q CME/CPD activities are intended to be evidence-based and free of commercial bias.

Speaker: Tania Jaber, MD, has nothing to disclose and will be discussing the use of approved oral chemotherapeutic agents for unlabeled use in thyroid cancer

Course Director/Planning Committee: Thurayya Arayssi, MD; **Planning Committee:** Aicha Hind Rifai, MD; Sohaila Cheema, MBBS; Sheila Qureshi, PhD; Therese Lanigan, MSc; Maria Paiva, BSP; Deema Al-Sheikhly, MRes, MEHP, Christopher R. Triggie, PhD, Thomas Hogan, BSc, DDS, Mary Parrott, RRN, MA – *have nothing to disclose*

Planning Committee: Stephen L. Atkin, MBBS *has disclosed the following:* Educational Lectures with Novo Nordisk

Coordinator: Laudy Mattar MM; Mariette D'Souza *have nothing to disclose*

CPD Staff: *Have nothing to disclose*

WCM-Q does not accept industry support for any regularly scheduled series. Any exceptions to this are approved by the CPD Oversight Committee, and will be disclosed prior to this presentation.

To be eligible to receive a certificate:

1. Sign-in at the beginning of each session.
2. Complete the evaluation form that is sent out after the lecture.